Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects and/or parent(s)/legally acceptable representative must be considered willing and able to sign consent, and complete daily seizure diaries and monitor seizure frequency.~* Male and female epilepsy subjects, 4 to 16 years of age inclusive on the date of the Screening Visit.~* Diagnosis of epilepsy with partial onset seizures classified as simple partial, complex partial or partial becoming secondarily generalized, according to the International League Against Epilepsy (ILAE) Diagnosis criteria.~* Must have a partial onset seizure frequency of at least 3 seizures per 28 day period prior to screening. Must have a partial onset seizure frequency of at least 6 seizures and no continuous 4 week seizure free period during the 8 week baseline phase prior to randomization.~* Currently receiving a stable dose of 1 to 3 antiepileptic drugs (stable within 28 days prior to screening).~Exclusion Criteria:~* Primary generalized seizures (including in the setting of co-existing partial onset seizures) which include, for example: Clonic, tonic and clonic-tonic seizures (note that partial onset seizures that become secondarily generalized are not exclusionary); Absence seizures; Infantile spasms; Myoclonic, myoclonic atonic, myoclonic tonic seizures.~* Lennox Gastaut syndrome, Benign Epilepsy with Centrotemporal Spikes (BECTS) and Dravet syndrome.~* A current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness. Any febrile seizures within 1 year of screening.~* Status epilepticus within 1 year prior to screening.~* Seizures related to drugs, alcohol, or acute medical illness.~* Any change in AED regimen (type of medication or dose) within 28 days of the Screening Visit or during the Baseline Phase.~* Progressive structural CNS lesion or a progressive encephalopathy.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin Level 1 (max 150 mg/day) (Type: EXPERIMENTAL): None
- Pregabalin Level 2 (max 600 mg day) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).